IL105827A - 10-substituted 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno [2,3-b][1,5] benzodiazepines their preparation and pharmaceutical compositions containing them - Google Patents

10-substituted 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno [2,3-b][1,5] benzodiazepines their preparation and pharmaceutical compositions containing them

Info

Publication number
IL105827A
IL105827A IL10582793A IL10582793A IL105827A IL 105827 A IL105827 A IL 105827A IL 10582793 A IL10582793 A IL 10582793A IL 10582793 A IL10582793 A IL 10582793A IL 105827 A IL105827 A IL 105827A
Authority
IL
Israel
Prior art keywords
methyl
benzodiazepines
thieno
piperazinyl
substituted
Prior art date
Application number
IL10582793A
Other languages
English (en)
Other versions
IL105827A0 (en
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of IL105827A0 publication Critical patent/IL105827A0/xx
Publication of IL105827A publication Critical patent/IL105827A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL10582793A 1992-05-29 1993-05-28 10-substituted 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno [2,3-b][1,5] benzodiazepines their preparation and pharmaceutical compositions containing them IL105827A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
IL105827A0 IL105827A0 (en) 1993-09-22
IL105827A true IL105827A (en) 1997-02-18

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10582793A IL105827A (en) 1992-05-29 1993-05-28 10-substituted 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno [2,3-b][1,5] benzodiazepines their preparation and pharmaceutical compositions containing them

Country Status (21)

Country Link
EP (1) EP0582368B1 (fr)
JP (1) JP3219541B2 (fr)
CN (1) CN1043994C (fr)
AT (1) ATE198891T1 (fr)
AU (1) AU668159B2 (fr)
CA (1) CA2097016A1 (fr)
CZ (1) CZ282783B6 (fr)
DE (1) DE69329887T2 (fr)
DK (1) DK0582368T3 (fr)
ES (1) ES2153373T3 (fr)
FI (1) FI101538B (fr)
GR (1) GR3035587T3 (fr)
HU (1) HU218278B (fr)
IL (1) IL105827A (fr)
MX (1) MX9303124A (fr)
MY (1) MY109943A (fr)
NO (1) NO305125B1 (fr)
NZ (1) NZ247703A (fr)
PT (1) PT582368E (fr)
RU (1) RU2125574C1 (fr)
TW (1) TW268005B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
WO1997035582A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Technique de traitement de la douleur due a la migraine
JP2000507945A (ja) * 1996-03-25 2000-06-27 イーライ・リリー・アンド・カンパニー 痛みを処置する方法
WO1997035583A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Procede de traitement de la douleur
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
CA2266444C (fr) * 1996-09-23 2007-01-09 Eli Lilly And Company Dihydrate d d'olanzapine
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
ES2669565T3 (es) 2012-08-21 2018-05-28 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
JP6216926B2 (ja) 2012-08-21 2017-10-25 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンに対する抗体及びその使用
CA2882597C (fr) 2012-08-21 2020-04-14 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre des haptenes de quetiapine et leur utilisation
CA2882563C (fr) 2012-08-21 2022-11-29 Eric Hryhorenko Anticorps diriges contre des haptenes de risperidone et leur utilisation
CA2882615C (fr) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre la quetiapine et leur utilisation
PL2888234T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
JP2015527365A (ja) 2012-08-21 2015-09-17 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンに対する抗体及びその使用
CN104837838A (zh) 2012-08-21 2015-08-12 詹森药业有限公司 帕潘立酮半抗原
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
AU2013305895B2 (en) 2012-08-21 2017-10-19 Saladax Biomedical Inc. Antibodies to olanzapine haptens and use thereof
EP2888257B1 (fr) 2012-08-21 2017-08-02 Janssen Pharmaceutica NV Haptènes de la quétiapine destinés à être utilisés dans des dosages immunologiques
EP3933406A3 (fr) 2012-08-21 2022-04-20 Janssen Pharmaceutica NV Anticorps pour rispéridone et utilisation associée
WO2014031603A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Anticorps dirigés contre des haptènes de palipéridone et leur utilisation
TR201816378T4 (tr) * 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Olanzapin haptenleri.
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
JP6994461B2 (ja) 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンに対する抗体及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
DE2641378A1 (de) * 1975-09-24 1977-04-07 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
FI932445A0 (fi) 1993-05-28
CA2097016A1 (fr) 1993-11-30
FI101538B1 (fi) 1998-07-15
NO931917L (no) 1993-11-30
HU218278B (en) 2000-07-28
NZ247703A (en) 1995-07-26
HUT66180A (en) 1994-09-28
MX9303124A (es) 1993-11-01
DK0582368T3 (da) 2001-02-05
ES2153373T3 (es) 2001-03-01
HU9301579D0 (en) 1993-09-28
FI932445A (fi) 1993-11-30
EP0582368B1 (fr) 2001-01-24
TW268005B (fr) 1996-01-11
DE69329887T2 (de) 2001-05-23
GR3035587T3 (en) 2001-06-29
EP0582368A1 (fr) 1994-02-09
CN1085903A (zh) 1994-04-27
JP3219541B2 (ja) 2001-10-15
AU668159B2 (en) 1996-04-26
ATE198891T1 (de) 2001-02-15
CZ102493A3 (en) 1993-12-15
NO305125B1 (no) 1999-04-06
RU2125574C1 (ru) 1999-01-27
CN1043994C (zh) 1999-07-07
JPH0687862A (ja) 1994-03-29
PT582368E (pt) 2001-05-31
CZ282783B6 (cs) 1997-10-15
MY109943A (en) 1997-10-31
DE69329887D1 (de) 2001-03-01
NO931917D0 (no) 1993-05-26
IL105827A0 (en) 1993-09-22
FI101538B (fi) 1998-07-15
AU3980793A (en) 1993-12-02

Similar Documents

Publication Publication Date Title
IL105827A (en) 10-substituted 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno [2,3-b][1,5] benzodiazepines their preparation and pharmaceutical compositions containing them
KR910018387A (ko) 약제학적 화합물
EG17753A (en) Novel pharmacological compounds
IL100572A (en) Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
IL132763A0 (en) Novel compounds
GR3019765T3 (en) Use of a dihydrothienopyridine-derivative for inhibiting the release of cerebral glutamate
IL114785A0 (en) Pyrrolocarbazoles their preparation and pharmaceutical compositions containing them
HUT64026A (en) Process for producing 4-alkyl-3-amino-2-chloropyridines
IL97999A0 (en) Pyrido(2,3-f)(1,4)thiazepines and pyrido(3,2-b)(1,5)-benzothiazepines,their preparation and pharmaceutical compositions containing them
HU895657D0 (en) Process for the preparation of mevalonolactones containing thienopyridine ring and pharmaceutical compositions containing such acitve ingredients
AU630575B2 (en) Benzodiazepine derivatives
IL107614A0 (en) Vitamin d3 analogs their preparation and pharmaceutical compositions containing them
ZA864444B (en) Pyrrolidone derivatives
ES2094913T3 (es) Metodo para la preparacion de 3-amino-2-cloro-4-alquilpiridinas.
UA41981C2 (uk) Біотинові сполуки, спосіб їх отримання, фармацевтична композиція та спосіб її отримання
TW275629B (fr)
HUP9902086A3 (en) Thieno[2,3-b]pyrazolo[3,4-d]pyridin-3-ones, their use, pharmaceutical compositions containing them, process for their preparation, intermediates
GB8823040D0 (en) Organic compounds & their use as pharmaceuticals
KR937000511A (ko) 신규한 화합물

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
RH1 Patent not in force